Fostering Further Collaboration between PMDA and Applicants with Efficient Project Management in Drug Development
|
|
- Sheena Clarke
- 7 years ago
- Views:
Transcription
1 Fostering Further Collaboration between PMDA and Applicants with Efficient Project Management in Drug Development Kazuishi Sekino Review Director Office of New Drug I Pharmaceuticals & Medical Devices Agency Pharmaceuticals and Medical Devices Agency, Japan
2 Disclaimer The views and opinions expressed in the following PowerPoint slides are those of the individual presenter and should not be attributed to DIA, its directors, officers, employees, volunteers, members, chapters, councils, Communities or affiliates, or any organization with which the presenter is employed or affiliated. These PowerPoint slides are the intellectual property of the individual presenter and are protected under the copyright laws of the United States of America and other countries. Used by permission. All rights reserved. DIA and the DIA logo are registered trademarks or trademarks of Drug Information Association Inc. All other trademarks are the property of their respective owners DIA, Inc. All rights reserved. 12th Annual Meeting DIA JAPAN 2015 November Tokyo Big Sight Ariake 2
3 Outline of Presentation 1. Current Situation of Approval Review 2. The Elements of Project and Priority 3. Progress Management of Approval Review Process 4. Progress Management of Scientific Advice process 2015 DIA, Inc. All rights reserved. 12th Annual Meeting DIA JAPAN 2015 November Tokyo Big Sight Ariake 3
4 Review Time for New Drugs (median) (Months) (Total review time = Regulatory review time + Applicant s time) The PMDA s Second Mid-term Plan The PMDA s Third Mid-term Plan (Numbers of approved products) FY2014 PMDA: Pharmaceuticals and Medical Devices Agency < DIA, Inc. All rights reserved. 12th Annual Meeting DIA JAPAN 2015 November Tokyo Big Sight Ariake 4
5 Six regulatory Authorities Approval Time of New Drugs in EU US Japan Canada Switzerland Australia Regulatory Affairs Professional Society 2015/1/ DIA, Inc. All rights reserved. 12th Annual Meeting DIA JAPAN 2015 November Tokyo Big Sight Ariake 5
6 The PMDA s Third Mid-term Plan(FY2014 to FY2018) The plan for prompt realization of zero review lag for new drugs Review Time for New Drugs (Priority Review) Total review time (Regulatory review time + Applicant s time);9 months(6 months + 3 months) Review Time for New Drugs (Standard Review) Total review time (Regulatory review time + Applicant s time) ;12 months(9 months + 3 months) Target percentile FY2014 FY2015 FY2016 FY2017 FY % 60% 70% 70% 80% PMDA: Pharmaceuticals and Medical Devices Agency < DIA, Inc. All rights reserved. 12th Annual Meeting DIA JAPAN 2015 November Tokyo Big Sight Ariake 6
7 Outline of Presentation 1. Current Situation of Approval Review 2. The Elements of Project and Priority 3. Project Management for Process of Approval Review 4. Project Management for Process of Scientific Advice 2015 DIA, Inc. All rights reserved. 12th Annual Meeting DIA JAPAN 2015 November Tokyo Big Sight Ariake 7
8 The Three Elements of Project and Priority Time (start and end time, the necessary time) Resource (reviewers) Project Scope, Quality (different each time) Top Priority (Mandatory Goal) Second Priority (Goal to Strive) Allowance Time Resource Scope, Quality プロジェクトマネジメント 理 論 編 ( 第 2 版 ) 総 合 法 令 出 版 一 部 改 変 2015 DIA, Inc. All rights reserved. 12th Annual Meeting DIA JAPAN 2015 November Tokyo Big Sight Ariake 8
9 Outline of Presentation 1. Current Situation of Approval Review 2. The Elements of Project and Priority 3. Project Management for Process of Approval Review 4. Project Management for Process of Scientific Advice 2015 DIA, Inc. All rights reserved. 12th Annual Meeting DIA JAPAN 2015 November Tokyo Big Sight Ariake 9
10 Flow of Review for New Drugs (in the past) Submission PMDA MHLW Pre- Submission Meeting NDA Filling PMDA s Evaluation List of Questions to Applicant PMDA s Evaluation External Expert Discussion PMDA s Opinion PAFSC Approval by MHLW Standard Review months Initial Meeting Assessment Report months months months months Standard Review: Total 12 months Priority Review: Total 9 months MHLW: Ministry of Health, Labour and Welfare NDA: New Drug Application PMDA: Pharmaceuticals and Medical Devices Agency PAFSC: Pharmaceutical Affairs and Food Safety Council 2015 DIA, Inc. All rights reserved. 12th Annual Meeting DIA JAPAN 2015 November Tokyo Big Sight Ariake <Administrative Notice of MHLW, March 30, 2012> 10
11 Pre-submission Meeting for Approval Review 2015 DIA, Inc. All rights reserved. 12th Annual Meeting DIA JAPAN 2015 November Tokyo Big Sight Ariake 11
12 Flow of Review for New Drugs (at present) Submission PMDA MHLW Pre- Submission Meeting NDA Filling PMDA s Evaluation List of Questions to Applicant PMDA s Evaluation External Expert Discussion PMDA s Opinion PAFSC Approval by MHLW Standard Review Priority Review 2.4 months 1.9 months Initial Meeting 0.6 months 0.3 months Assessment Report 5.7 months 1.5 months 0.9 months 4.4 months 1.3 months 0.8 months Standard Review: 12 months Priority Review: 9 months MHLW: Ministry of Health, Labour and Welfare NDA: New Drug Application PMDA: Pharmaceuticals and Medical Devices Agency PAFSC: Pharmaceutical Affairs and Food Safety Council 2015 DIA, Inc. All rights reserved. 12th Annual Meeting DIA JAPAN 2015 November Tokyo Big Sight Ariake <Administrative Notice of MHLW, January 30, 2015> 12
13 Outline of Presentation 1. Current Situation of Approval Review 2. The Elements of Project and Priority 3. Project Management for Process of Approval Review 4. Project Management for Process of Scientific Advice 2015 DIA, Inc. All rights reserved. 12th Annual Meeting DIA JAPAN 2015 November Tokyo Big Sight Ariake 13
14 Flow of Scientific Advice for New Drug Development Applicant s Action Intention to Apply Submission of Document Response to List of Questions Response to PMDA s Opinion Pre- Submission Meeting Scheduling Preparing Document PMDA s Evaluation List of Questions to Applicant PMDA s Evaluation PMDA s Opinion to Applicant Face to Face Meeting Minutes 1 week (2-5 weeks) (1 week) 1 week (1 week) 1 week 1 month 2 months (8-11 weeks) 5 weeks PMDA: Pharmaceuticals and Medical Devices Agency 2015 DIA, Inc. All rights reserved. 12th Annual Meeting DIA JAPAN 2015 November Tokyo Big Sight Ariake 14
15 Number of Scientific Advice for New Drugs (Review Category 1; Gastrointestinal Drugs etc.) (N) < DIA, Inc. All rights reserved. 12th Annual Meeting DIA JAPAN 2015 November Tokyo Big Sight Ariake 15
16 US & EU Japan Example of the GANNT chart (I) Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q Hypothetical situation Best timing? Reflection of PMDA s opinion to protocol? Top-Line Results Scientific Advice PMDA PMDA Applicant s Decision Making Phase I trial Phase II trial Delay of enrollment of Japanese patients? FDA, EMA FDA, EMA Global Phase III trial Phase I trial Phase II trial EMA: European Medicines Agency FDA: US Food and Drug Administrationl PMDA: Pharmaceuticals and Medical Devices Agency 2015 DIA, Inc. All rights reserved. 12th Annual Meeting DIA JAPAN 2015 November Tokyo Big Sight Ariake 16
17 US & EU Japan Example of the GANNT chart (II) Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q Hypothetical situation Best timing? Phase I trial PMDA Reflection of PMDA s opinion to protocol? Best road map? FDA, EMA, PMDA Top-Line Results Scientific Advice Applicant s Decision Making FDA, EMA Global Phase II trial Global Phase III trial Phase I trial Phase IIa trial EMA: European Medicines Agency FDA: US Food and Drug Administrationl PMDA: Pharmaceuticals and Medical Devices Agency 2015 DIA, Inc. All rights reserved. 12th Annual Meeting DIA JAPAN 2015 November Tokyo Big Sight Ariake 17
18 Items for the Project Management Time (starting and ending time, the required time) Project Resource (reviewers) Examples of items for the project management The target product profile The strategic development plan (and current status) The GANNT chart (development history and project scheduling, including discussion to regulatory agencies) etc. Scope, Quality (different each time) Effective utilization of pre-submission meeting (sharing the information between applicant and PMDA) プロジェクトマネジメント 理 論 編 ( 第 2 版 ) 総 合 法 令 出 版 一 部 改 変 PMDA: Pharmaceuticals and Medical Devices Agency 2015 DIA, Inc. All rights reserved. 12th Annual Meeting DIA JAPAN 2015 November Tokyo Big Sight Ariake 18
19 Thank you for your attention. Welfare of patients! DIA, Inc. All rights reserved. 12th Annual Meeting DIA JAPAN 2015 November Tokyo Big Sight Ariake 19
20 Ask
CDISC standards and data management The essential elements for Advanced Review with Electronic Data
Session 6: Toward Electronic Submission of Study Data for New Drug Applications CDISC standards and data management The essential elements for Advanced Review with Electronic Data Yuki Ando Senior Scientist
More informationICD-9-CM to MedDRA Mapping How Well Do the. Disclaimer
ICD-9-CM to MedDRA Mapping How Well Do the Two Terminologies Correlate Anna Zhao-Wong, MD, PhD Deputy Director MedDRA MSSO Disclaimer The views and opinions expressed in the following PowerPoint slides
More informationJapan PMDA and CDISC Standards. Yuki Ando Senior Scientist for Biostatistics Pharmaceuticals and Medical Devices Agency (PMDA)
Japan PMDA and CDISC Standards Yuki Ando Senior Scientist for Biostatistics Pharmaceuticals and Medical Devices Agency (PMDA) CDISC 2012 1 Outline New drug review process in Japan Task force for advanced
More informationStakeholders identification: key success factor for the implementation of Electronic Document Management Systems
Stakeholders identification: key success factor for the implementation of Electronic Document Management Systems Isabel Saez-Pujol Director, Informatics & Knowledge Management Daiichi Sankyo Development,
More information2009 Life Sciences Industry Document Management/Collaboration Survey. DIA Disclaimer. 2009 Benchmark / Survey Objectives
2009 Life Sciences Industry Document Management/Collaboration Survey Conducted and Prepared by International Life Science Solutions & Associates 10 th EU EDM Meeting Vienna, Austria, 2009 DIA Disclaimer
More informationOverview of CDISC Implementation at PMDA. Yuki Ando Senior Scientist for Biostatistics Pharmaceuticals and Medical Devices Agency (PMDA)
Overview of CDISC Implementation at PMDA Yuki Ando Senior Scientist for Biostatistics Pharmaceuticals and Medical Devices Agency (PMDA) CDISC 2012 Outline Introduction Update of PMDA activity CDISC implementation
More informationHow Industry Can Partner with FDA in Defining a Risk- Based Monitoring Program
How Industry Can Partner with FDA in Defining a Risk- Based Monitoring Program Presenter: Jan Holladay Pierre, MPH Quality Principal Leader DynPort Vaccine Company LLC, A CSC Company This presentation
More informationCertification for Data Managers- How high is the bar?
Certification for Data Managers- How high is the bar? Linda M. Talley, CCDM International Network of Clinical Data Management Associations-(INCDMA) Chair Society for Clinical Data Management (SCDM)- Chair
More informationEVALUATION AND RECOMMENDATION OF PHARMACOPOEIAL TEXTS FOR USE IN THE ICH REGIONS ON TABLET FRIABILITY GENERAL CHAPTER Q4B ANNEX 9(R1)
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE EVALUATION AND RECOMMENDATION OF PHARMACOPOEIAL
More informationHow Transparent are Regulatory Agencies with regard to Review Timelines? Disclaimer
How Transparent are Regulatory Agencies with regard to Review Timelines? A Global Review Rosanna Melchior Sr Manager, Reg.Intelligence THOMSON REUTERS, France Disclaimer The views and opinions expressed
More informationISO Identification of Medicinal Products (IDMP) and HL7 Structured Product Labeling (SPL) Disclaimer
ISO Identification of Medicinal Products (IDMP) and HL7 Structured Product Labeling (SPL) Vada Perkins, CAPT, USPHS US Food and Drug Administration/ Center for Biologics Evaluation and Research 11 October
More informationFDA's Module 1 Update: From Ideas to Implementation. Jared C. Lantzy, PMP
FDA's Module 1 Update: From Ideas to Implementation Jared C. Lantzy, PMP The views and opinions expressed in the following PowerPoint slides are those of the individual presenter and should not be attributed
More informationAn Overview of the Medical Devices Single Audit Program
Your health and safety our priority. Votre santé et votre sécurité notre priorité. An Overview of the Medical Devices Single Audit Program Nancy Shadeed Bureau of Policy, Science and International Programs
More informationRisk Management Plan (RMP) Guidance (Draft)
Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour and Welfare Translated by Pharmaceuticals and Medical Devices Agency Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour
More informationMed-Info. New Act on Medical Devices in Japan. TÜV SÜD Product Service GmbH. International expert information for the Medical Device industry
Med-Info International expert information for the Medical Device industry New Act on Medical Devices in Japan New Act on Medical Devices (PMD Act) to be launched on November 25, 2014 Practice-oriented
More informationPost-Approval Change Management: Challenges and Opportunities An FDA Perspective
CMC Workshop From Drug Development to Global Supply to Patients April 15-17, 2013, Washington, DC Post-Approval Change Management: Challenges and Opportunities An FDA Perspective Christine M. V. Moore,
More informationWhy Are Drugs So Expensive? Learning About the Drug Development Process
Why Are Drugs So Expensive? Page 1 of 92 Why Are Drugs So Expensive? Learning About the Drug Development Process written by: Ann Newman Seventh Street Development Group This product is for your Personal
More informationGMP and QMS Regulation in Japan
GMP and QMS Regulation in Japan Tomiko Tawaragi Chief Safety Officer Pharmaceuticals and Medical Devices Agency (PMDA) August 2 nd, 2014 1 st Brazil-Japan Seminar GMP/QMS GMP : Good Manufacture Practice
More informationPharmaceuticals and Medical Devices Agency, Japan. Fiscal Year 2010
Pharmaceuticals and Medical Devices Agency, Japan Fiscal Year 2010 Greetings Outline of the Pharmaceuticals and Medical Devices Agency (PMDA) Services of PMDA Relief Services for Adverse Health Effects
More informationand Regulatory Aspects
Good Clinical Practice and Regulatory Aspects Nora Espiritu MD, MPh, PhD (c) Former Executive Director of Research and Technology Transfer. Peruvian National Institute t of Health. Member of the Ethics
More informationSafety Risk Assessment in Drug Development
Safety Risk Assessment in Drug Development The LA Regional Experience Terezinha C. Teotonio, RN, MSN PPD LA PVG Manager Lessons Learned Globally Need for testing prior to marketing Need for regulations
More informationClinical trials in haemophilia
Clinical trials in haemophilia Dr. Paul Giangrande Oxford Haemophilia and Thrombosis Centre & Nuffield Department of Clinical Medicine University of Oxford paul.giangrande@ndm.ox.ac.uk Why do clinical
More informationHistory and Principles of Good Clinical Practice
History and Principles of Good Clinical Practice Cristina E. Torres, Ph.D. Social Science Professor, UPM-NIH FERCAP Coordinator ICH: International Conference on Harmonization GCP: Good Clinical Practices
More informationRegistration of Class B Medical Devices
Registration of Class B Medical Devices 1 INTRODUCTION Medical devices are classified based on a rule based risk classification system into four risk classes Class A to D with Class A being the lowest
More informationSafety Is Global: Contemporary Pharmacovigilance and Medical Product Risk Management Strategies
Safety Is Global: Contemporary Pharmacovigilance and Medical Product Risk Management Strategies CLICK HERE to register. PROGRAM COMMITTEE WHO SHOULD ATTEND This program will benefit professionals with
More informationIntroduction to Q10 Pharmaceutical Quality System
ICH-GCG Asean Training Workshop on ICH Guidelines Q8,Q9 and Q10 (New Paradigm) Introduction to Q10 Pharmaceutical Quality System Georges FRANCE, Q- IWG Kuala Lumpur, Malaysia 26-28 July 2010 International
More informationQuality by Design Concept
3rd Jerusalem Conference on Quality and Pharma Sciences 6-7 June, 2012 QbD in Clinical Research - Where Can QbD Impact Clinical Research Practices? Dr. Yafit Stark Vice President, TEVA Pharmaceutical Industries,
More informationPEDIATRIC MEDICINES: GLOBAL MARKETS
PEDIATRIC MEDICINES: GLOBAL MARKETS PHM170A October 2014 Dr. Cheryl Lee Barton Project Analyst ISBN: 1-56965-971-0 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215 (toll-free
More informationBring Your Own Device (BYOD) Approaches To The Collection Of Electronic Patient Reported Outcome Data
Bring Your Own Device (BYOD) Approaches To The Collection Of Electronic Patient Reported Outcome Data Chad Gwaltney, Ph.D. Chief Scientist and Regulatory Advisor, Endpoints 1 Disclaimer The views and opinions
More informationOverview of Risk Management
Overview of Risk Management Risk Management Plans- An Industry Perspective Dr. Sudhichai Chokekijchai, CSO Novartis (Thailand) Limited (adapted from an RMP training by Dr Judith Sills, Global Head, Medical
More informationUNDERSTANDING THE EC DIRECTIVE 98/79/EC ON IN VITRO DIAGNOSTIC MEDICAL DEVICES
UNDERSTANDING THE EC DIRECTIVE 98/79/EC ON IN VITRO DIAGNOSTIC MEDICAL DEVICES A WHITE PAPER ON THE REQUIREMENTS, REGULATIONS AND OPPORTUNITIES CONTAINED IN EC DIRECTIVE 98/79/EC AND A BRIEF COMPARISON
More informationApplication for Accreditation of Foreign Manufacturers
Application for Accreditation of Foreign Manufacturers (This English document is only for reference purpose. In case of any discrepancy, the Japanese text shall prevail. For further information, please
More informationwhite paper Conducting Clinical Trials in Japan: A CRO Perspective
white paper Conducting Clinical Trials in Japan: A CRO Perspective ppdi.com October 2013 Yasmine Chiu, M.D. Senior Medical Director, Pharmacovigilance, PPD INTRODUCTION Japan is the world s second-largest
More informationMedical Device Marketing Authorization System (MDMA) MDMA User Manual
Medical Device Marketing Authorization System (MDMA) MDMA User Manual FOR THE Saudi Food & Drug Authority Document Version: ١ Date: April, ٤ th, ٢٠١١ Table of Contents FOR THE... ١ Saudi Food & Drug Authority...
More informationOECD Recommendation on the Governance of Clinical Trials
OECD Recommendation on the Governance of Clinical Trials Marketing authorisation status of the medicinal products Non-authorised medicine Authorised medicine, treatment regimen outside
More informationCenterWatch. volunteering. clinical trial. for a. www.centerwatch.com
volunteering for a clinical trial www.centerwatch.com :: about this pamphlet This pamphlet provides an overview of the clinical trials process and answers frequently asked questions that many potential
More informationData Management and Good Clinical Practice Patrick Murphy, Research Informatics, Family Health International
Data Management and Good Clinical Practice Patrick Murphy,, Family Health International 1 What is GCP? Good Clinical Practice is an international ethical and scientific quality standard for designing,
More informationPharmaceutical Quality & Clinical Research Quality: The Interaction
4 th Jerusalem Conference: Quality by Design (QbD)) & Pharma Sciences, May 20-22, 2014 The Edmund Safra Campus, The Hebrew University of Jerusalem Pharmaceutical Quality & Clinical Research Quality: The
More informationTarget Product Profile (TPP) Process. Dr. Michele Sharp, PharmD, Sr. Director, Regulatory Affairs, Eli Lilly and Company
Target Product Profile (TPP) Process Dr. Michele Sharp, PharmD, Sr. Director, Regulatory Affairs, Eli Lilly and Company 1 Disclaimer The views and opinions expressed in the following PowerPoint slides
More informationEMA Update Clinical Trials
EMA Update Clinical Trials Fergus Sweeney, Head, Compliance and Inspections, European Medicines Agency 16 October 2012 An agency of the European Union Disclaimer The views presented in this presentation/these
More informationMeetings with CDER Judit Milstein
Meetings with CDER Judit Milstein Division of Transplant and Ophthalmology Products (DTOP) Office of Antimicrobial Products (OAP), Office of New Drugs (OND) Center for Drug Evaluation and Research (CDER)
More informationEU PAS Register Guide
29 March 2016 EMA/613603/2012 (currently ENCePP E-Register of Studies) The EU PAS Register is temporarily hosted on the ENCePP website www.encepp.eu 1. Introduction... 2 2. ENCePP E-Register as a temporary
More informationManaging Clinical Operations Risks. Lars Schmiedeberg
Managing Clinical Operations Risks Lars Schmiedeberg Disclaimer The views and opinion expressed in this slides are that of the presenter and do not necessarily reflect the views and opinions of ii4sm ltd.
More informationGMP/Regulatory Environment in the
GMP/Regulatory Environment in the Latin America Irene Ortiz Barreal, Pharm. D., R.Ph. Pfizer International Affiliate Quality Compliance Regional Leader Latin America/Caribbean April 14, 2011 Discloser
More informationIncrease Hepatitis C Virus Screening and Treatment
18 Increase Hepatitis C Virus Screening and Treatment Situation The number of deaths from liver cancer in Japan has been rising rapidly since 1975, and now stands at more than 30,000 per year. About 80
More informationDiagnostic Tests. Brad Spring Director, Regulatory Affairs
Regulatory Challenges in the Development of Diagnostic Tests Industry Perspective Brad Spring Director, Regulatory Affairs September 28, 2011 Balancing Evidence of Safety & Effectiveness and Time to Market
More informationIntroduction. 1. General outline. 1) Position of the Healthcare Policy. 2) Basic principles of the Healthcare Policy (Article 2 of the Promotion Act)
Overview of the Healthcare Policy Introduction For Japan, which is becoming an ultra-aging society ahead of other countries, it is important to realize the world s most advanced medical technologies and
More informationCompany Profile. 1-2-1 Osaki, Shinagawa-ku, Tokyo, 141-8672 Japan Tel. +81 3 5435 7777 www.hitachi-systems.com/eng/
Company Profile 1-2-1 Osaki, Shinagawa-ku, Tokyo, 141-8672 Japan Tel. +81 3 5435 7777 www.hitachi-systems.com/eng/ All product and company names in this document are trademarks or registered trademarks
More informationComparing GCP Requirements for Medical Device Clinical Trials in the US and Japan
REGULATORY MANAGER Comparing GCP Requirements for Medical Device Clinical Trials in the US and Japan By Harmonization-by-Doing Working Group 4 Introduction The convergence of US and Japanese medical device
More informationThe views and opinions expressed in the following PowerPoint slides are
Electronic Tools and Gadgets Julie P. Retzinger RN, MBA Baxter Healthcare The views and opinions expressed in the following PowerPoint slides are those of the individual id presenter and should not be
More informationMedical Information Role in the Pharmaceutical Industry
www.arisglobal.com A White Paper Presented By ArisGlobal Medical Information Role in the Pharmaceutical Industry by Ome Ogbru, PharmD, Medical Information, SME What is Medical Information Overview Medical
More informationCourse Certificate In. Pharmaceuticals and Medical Research: Clinical Research Monitoring & Coordination
Course Certificate In Pharmaceuticals and Medical Research: Clinical Research Monitoring & Coordination Welcome to the latest in distance learning courses designed to prepare you, on your own schedule,
More informationMarketing Authorization Procedures in the European Union Making the Right Choice
Life science i technical bulletin ISSUE N 33 /DECEMBER 2009 Marketing Authorization Procedures in the European Union Making the Right Choice AUTHOR: Arash Ghalamkarpour, PhD, Regulatory Affairs Associate,
More informationDrug Development Models in China and the Impact on Multinational Pharmaceutical Companies
Drug Development Models in China and the Impact on Multinational Pharmaceutical Companies By Ling Su, Ph.D. China represents a huge potential opportunity for the pharmaceutical industry in both commercial
More informationMigration of Controlled. Compliant SharePoint Document Management Systems. Presented by: Joe Lucadamo
Migration of Controlled Documents into Compliant SharePoint Document Management Systems Presented by: Joe Lucadamo Focused dconsulting The views and opinions expressed in the following PowerPoint slides
More informationOur name ASPHALION derives from the Greek word asphaléia, alluding to values such as firmness, stability, certainty and reliability.
Company Profile Our History ASPHALION is an International Drug Development and Regulatory Affairs consultancy firm founded in 2000, with an international team of over 40 people. Our Values Our name ASPHALION
More informationProspect of ICT Utilization at Core Clinical Research Hospitals
Prospect of ICT Utilization at Core Clinical Research Hospitals Koki Akahori One of Fujitsu s endeavors in healthcare is to develop coordinated solutions for medicine and pharmaceuticals, and is focusing
More informationAdopting Site Quality Management to Optimize Risk-Based Monitoring
Adopting Site Quality Management to Optimize Risk-Based Monitoring Medidata and other marks used herein are trademarks of Medidata Solutions, Inc. All other trademarks are the property of their respective
More informationPediatric Research Networks A Plan for a Collaboration in Europe. Daniela Gunz Head Clinical Trial Operations Switzerland June 9, 2011
Pediatric Research Networks A Plan for a Collaboration in Europe Daniela Gunz Head Clinical Trial Operations Switzerland June 9, 2011 Agenda Challenges in clinical research in children EU pediatric regulation
More informationSubmission of comments on 'Policy 0070 on publication and access to clinical-trial data'
EMA/240810/2013 Submission of comments on 'Policy 0070 on publication and access to clinical-trial data' s from: Name and affiliation PHARMIG - Association of the Austrian pharmaceutical industry Please
More informationWhy Monitoring Is More Than Just SDV
Why Monitoring Is More Than Just SDV Medidata and other marks used herein are trademarks of Medidata Solutions, Inc. All other trademarks are the property of their respective owners. Copyright 2013 Medidata
More informationINTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE Q4B ANNEX 12
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE EVALUATION AND RECOMMENDATION OF PHARMACOPOEIAL
More informationDisclaimer. www.diahome.org
Disclaimer The views and opinions expressed in the following PowerPoint slides are those of the individual presenter and should not be attributed to Drug Information Association, Inc. ( DIA ), its directors,
More informationElectronic Health Records for Clinical Research. EHR Compliant to Clinical Trial Requirements. Oct 2009 1. Disclaimer
Electronic Health Records for Clinical EHR Compliant to Clinical Trial Requirements Mathias Poensgen EHRCR project / Aris Global Oct 2009 1 Disclaimer The views and opinions expressed in the following
More informationGLOBAL EDUCATION PROGRAM
GLOBAL EDUCATION PROGRAM RUSSIAN FEDERATION GOVERNMENT-SPONSORED PROGRAM THAT OFFERS RUSSIAN CITIZENS AN OPPORTUNITY TO STUDY AT LEADING FOREIGN UNIVERSITIES REGULATIONS: ABOUT GEP http://educationglobal.ru/o_programme/
More informationRisk Management Plan (RMP) on Biologicals and NCE
Transformation towards a New Regulatory Paradigm Risk Management Plan (RMP) on Biologicals and NCE Junko SATO International Coordination Officer PMDA, Japan 1 2 Pharmaceuticals and Medical Devices Agency
More information1 www.imarcresearch.com
Risk Management in Clinical Research: PROCESS DEVELOPMENT & APPLICATION Introduction Recently, two key pieces of guidance were released from Food and Drug Administration (FDA) and European Medicines Agency
More informationMedical Product Development Certificate Program
Life Sciences Medical Product Development Certificate Program Accelerate Your Career extension.uci.edu/mpd In today s competitive business environment, leaders are appointed based on credentials and experience.
More informationUnderstanding the Japanese culture and approval process
Paper RC04 Understanding the Japanese culture and approval process Richard Harvey, AstraZeneca, Macclesfield, UK ABSTRACT Gaining approval for a drug product in the West is a well-understood and documented
More informationResearch Administration at the University of Maryland
Research Administration at the University of Maryland Anne S. Geronimo, M.S. Director, Research Development Division of Research University of Maryland June 2007 Tokyo, Japan University of Maryland Profile
More informationMedical Devices. Notified Bodies and the CE certification Process for Medical Devices. European Surgical Robotics Demonstration Day
Medical Devices Notified Bodies and the CE certification Process for Medical Devices European Surgical Robotics Demonstration Day 27 th March 2014, Leuven, Belgium 1 Bart Mersseman Product Manager Medical
More informationEnterprise RIM: Building the Business Case. Steve Gens. Bethesda Maryland: February 25, 2014. Managing Partner Gens and Associates, Inc.
Enterprise RIM: Building the Business Case Bethesda Maryland: February 25, 2014 Steve Gens Managing Partner Gens and Associates, Inc. Disclaimer The views and opinions expressed in the following PowerPoint
More informationU.S. Food and Drug Administration
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA s website for reference purposes only. It was current when produced, but is no longer maintained
More informationCoding with MedDRA. MedDRA and the MSSO
Coding with MedDRA MedDRA is a registered trademark of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) MedDRA and the MSSO International support and development of
More informationA CRO's Dilemma - The CDMS Validation Package that Failed Client Audits 19.OCT.2009 1. Disclaimer
A CRO's Dilemma - The CDMS Validation Package that Failed Client Audits Teri Stokes, Ph.D., Director GXP International Concord, MA - USA Common Sense Computer Validation 19.OCT.2009 1 Disclaimer The views
More informationKey considerations for outsourcing late phase clinical research
Key considerations for outsourcing late phase clinical research Alan Nelson (on behalf of Van Zyl Engelbrecht) Senior Project Director at UBC: An Express Script Company Layout of presentation My presentation
More informationQ3 2015 Financial Results and Corporate Update. November 4, 2015
Q3 2015 Financial Results and Corporate Update November 4, 2015 Introductions and Forward- Looking Statements Silvia Taylor, SVP Investor Relations and Corporate Affairs Agenda Introductions and Forward-Looking
More informationCurrent Status of Databases in Japan
Current Status of Databases in Japan 2012.03 Kiyoshi Kubota, MD, PhD, FISPE Department of Pharmacodpiemiology, Graduate School of Medicine, University of Tokyo Kubotape-tky@umin.ac.jp NPO Drug Safety Research
More informationUNIQUE DEVICE IDENTIFICATION. and in the European Union. Laurent SELLES Senior Coordinator for International Relations Health Technology and Cosmetics
GLOBAL GS1 HEALTHCARE CONFERENCE Copenhagen Denmark 22 October 2014 UNIQUE DEVICE IDENTIFICATION Situation in the International Medical Device Regulators Forum (IMDRF) and in the European Union Laurent
More informationRegulatory approval routes in the European System for Medicinal Products
Regulatory approval routes in the European System for Medicinal Products Cardiovascular Combination Pharmacotherapy Global Summit, Melbourne, 8 th May 2014 Presented by: Kevin Blake Human Medicines Research
More informationREGULATORY ENVIRONMENT
1. Introduction REGULATORY ENVIRONMENT Research and development work, pre-clinical tests, clinical studies, facilities, and the manufacture and sale of the Company s products are and will continue to be
More informationPost-authorisation safety studies and the EU PAS Register
Post-authorisation safety studies and the EU PAS Register Xavier Kurz European Medicines Agency EMA, 11 October 2012 An agency of the European Union Content of the presentation 1. PASS: definition and
More informationSingapore Clinical Trials Register. Foo Yang Tong Director Clinical Trials Branch Health Products Regulation Group HEALTH SCIENCES AUTHORITY
Singapore Clinical Trials Register Foo Yang Tong Director Clinical Trials Branch Health Products Regulation Group HEALTH SCIENCES AUTHORITY Clinical Trial Register Global Trend EMA: EU Clinical Trials
More informationSafety Risk Management Company Perspective
Safety Risk Management Company Perspective Akihisa Harada, MD, Ph.D VP, Development Japan Pfizer Japan Inc. R&D Head Club Agenda REMS in FDAAA Safety Risk Management throughout a Drug s Lifecycle Risk
More informationAn FDA Perspective on Post- Approval Change Management for PAT and RTRT
An FDA Perspective on Post- Approval Change Management for PAT and RTRT IFPAC 2015 January 26, 2015 Christine M. V. Moore, Ph.D. Acting Director, Process and Facilities FDA/CDER/OPQ Post-Approval Changes
More informationBarriers and Solutions for the Expansion of Clinical Research in Latin America
Barriers and Solutions for the Expansion of Clinical Research in Latin America A Pharmaceutical Company s Perspective E. Isola DIA S. Paulo Sep 06 Outline Regulatory Culture Ethical issues Sponsors Patients
More informationSharing Industry Clinical Trial Data: Improving Public Health While Maintaining the Oversight Relationship Between Regulator and Sponsor
Sharing Industry Clinical Trial Data: Improving Public Health While Maintaining the Oversight Relationship Between Regulator and Sponsor Steven Snapinn SCT/QSPI/FDA Workshop Innovations in the Science
More informationCareers in Medical and Scientific Writing
Careers in Medical and Scientific Writing Laura McCormick, PhD Vice President Associate Practice Leader Tamara Fink, PhD Associate Scientific Director ProEd Communications, Inc Beachwood, Ohio Agenda Introduction
More informationUse of MedDRA in CTCAE and in the Biopharmaceutical Industry
Use of MedDRA in CTCAE and in the Biopharmaceutical Industry Ann Setser, BSN, MEd MedDRA MSSO MedDRA is a registered trademark of the International Federation of Pharmaceutical Manufacturers and Associations
More informationElectronic patient diaries in clinical research
Topics Electronic diaries in Clinical Trials Electronic diaries versus Paper Electronic patient diaries in clinical research Case Study: Novel detection of exacerbations of COPD with patient reported outcome
More informationIntroduction to the CTA & NDA process in China
Introduction to the CTA & NDA process in China Jie Zhang, Regulatory Affairs, Abbott China Presented by: Peter van Amsterdam, Clinical Pharmacology & Bioanalytics, Abbott Netherlands EBF/CBF China Days,
More information3rd China - Japan Symposium on Drug Development- focusing on Current Status of
3rd China - Japan Symposium on Drug Development- focusing on Current Status of Global Clinical Trials, Utilization of Clinical Data and Clinical Trial Consultation System - February 9, 2012 Pharmaceuticals
More informationGLOBAL EDUCATION PROGRAM
GLOBAL EDUCATION PROGRAM RUSSIAN GOVERNMENT-SPONSORED SCHOLARSHIP PROGRAM THAT OFFERS RUSSIAN CITIZENS AN OPPORTUNITY TO STUDY AT LEADING FOREIGN UNIVERSITIES КSENIA IVANENKO REGULATIONS: ABOUT GEP http://educationglobal.ru/o_programme/
More informationRegulatory strategies for small companies /SMEs
TOPRA Module 1 Strategic planning in RA Regulatory strategies for small companies /SMEs A presentation by Ineke Jonker-Hoogerkamp, Director Regulatory Affairs Neurology, Genzyme Europe BV Learning Outcomes
More informationWhite Paper January 2009. Top Ten Reports in Clinical Performance Management
White Paper January 2009 Top Ten Reports in Clinical Performance Management 2 Contents 3 The solution Clinical Performance Management Clinical Trail Resource Planning Reports Report #1 Clinical Trial Project
More informationClinical Trials and SPA Fall, 2014
Clinical Trials and SPA Fall, 2014 Laura Williams Frances Spalding Sponsored Projects Administration What to Expect Review of key clinical trial concepts A common clinical trial process How SPA fits in
More informationSchool of Pharmacy TEMPLE UNIVERSITY
School of Pharmacy TEMPLE UNIVERSITY Regulatory Affairs and Quality Assurance Graduate Program Te mple Unive rsity School of Pharmacy Re gulatory Affairs and Quality Assurance Graduate Program 4 25 Comme
More informationPharmaceutical Companies and Medical Publishers Working together in a world of increasing regulation
Pharmaceutical Companies and Medical Publishers Working together in a world of increasing regulation Sarah L Feeny Head of Scientific Direction, Complete Medical Communications Board of Trustees, International
More informationMedidée Services SA. Nano-Tera.ch. 05 February 2015 part 12. Special Issues Q&A Session. Michael Maier michael.maier@medidee.com www.medidee.
Nano-Tera.ch 05 February 2015 part 12 Special Issues Q&A Session Michael Maier michael.maier@medidee.com www.medidee.com Questions you asked 1/17 In WHICH cases to seek approval 1 - Please provide us with
More informationThe Japan Society of Mechanical Engineers C 2010
The Japan Society of Mechanical Engineers C 2010 The Japan Society of Mechanical Engineers 2010 C The Japan Society of Mechanical Engineers 2010 C The Japan Society of Mechanical Engineers C 2010 The Japan
More information